MiNK Therapeutics (INKT) Interest Expenses (2020 - 2026)
MiNK Therapeutics (INKT) posted Interest Expenses of -$4000.0 for Q1 2026, up 96.56% sequentially from -$116163.0 in Q4 2025, and up 86.21% YoY from -$2148.1 in Q1 2025.
MiNK Therapeutics (INKT) Interest Expenses (2020 - 2026) Analysis & Trends
MiNK Therapeutics has reported Interest Expenses for 7 years, with the latest figure at -$4000.0 in Q1 2026.
- Quarterly Interest Expenses rose 86.21% year-over-year to -$4000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$73028.0 (down 493.53% YoY) and the FY2025 annual result came in at $31.7 million, up 2169.19% from the prior year.
- Interest Expenses improved to -$4000.0 in Q1 2026 per INKT's latest filing, from -$116163.0 in the prior quarter.
- Over five years, Interest Expenses peaked at $6.2 million in Q3 2025 and troughed at -$116163.0 in Q4 2025.
- A 5-year average of $2.1 million and a median of $1.5 million in 2024 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2022 and 2023: Interest Expenses surged 674.21% in 2022, then tumbled 697.52% in 2023.
- Over 5 years, Interest Expenses stood at $8274.0 in 2022, then sank by 697.52% to -$49439.0 in 2023, then jumped by 254.0% to $76135.0 in 2024, then plunged by 252.58% to -$116163.0 in 2025, then soared by 96.56% to -$4000.0 in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered -$4000.0, -$116163.0, and $6.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | MiNK Therapeutics | 60.53 Mn | 60.53 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.33 Mn |
| Jun 30, 2026 | 4.33 Mn |
| Mar 31, 2026 | -4,000.00 |
| Mar 31, 2026 | -4,000.00 |
| Dec 31, 2025 | -116,163.00 |
| Dec 31, 2025 | -116,163.00 |
| Sep 30, 2025 | 6.22 Mn |
| Sep 30, 2025 | 6.22 Mn |
| Jun 30, 2025 | 1.38 Mn |
| Jun 30, 2025 | 1.38 Mn |
| Mar 31, 2025 | -29,000.00 |
| Mar 31, 2025 | -29,000.00 |
| Dec 31, 2024 | 76,135.00 |
| Dec 31, 2024 | 76,135.00 |
| Sep 30, 2024 | 1.51 Mn |
| Sep 30, 2024 | 1.51 Mn |
| Jun 30, 2024 | 2.10 Mn |
| Jun 30, 2024 | 2.10 Mn |
| Mar 31, 2024 | -10,000.00 |
| Mar 31, 2024 | -10,000.00 |